Brii Biosciences (Brii Bio) is a company committed to serving patients’ needs and improving public health in China. Founded in early 2018, the company focuses on accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese healthcare systems and access to the world’s second largest pharmaceutical market. The company’s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. The company is headquartered in the People’s Republic of China and the United States, with offices in Shanghai, Beijing, San Francisco, and Durham, North Carolina.